Trial Profile
To assess the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Nov 2017
Price :
$35
*
At a glance
- Drugs Darifenacin (Primary) ; Fesoterodine (Primary) ; Oxybutynin (Primary) ; Solifenacin (Primary) ; Tolterodine (Primary) ; Trospium chloride (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 23 Nov 2017 New trial record
- 13 Nov 2017 Results assessing cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark, were published in the European Journal of Clinical Pharmacology.